Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy

Area of Science:

• Neurology
• Immunology
• Autoimmune Diseases

Background:

• Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and idiopathic inflammatory myopathies are key autoimmune neuromuscular disorders.
• These conditions, despite varied clinical presentations, share underlying immunopathogenic mechanisms at a molecular level.

Purpose of the Study:

• To review current knowledge on pathogenic mechanisms in autoimmune neuromuscular disorders.
• To analyze the link between these mechanisms and emerging immunotherapies.
• To outline similarities, distinctions, and challenges in diagnosis and treatment.

Main Methods:

• Literature review of pathogenic mechanisms in autoimmune neuromuscular disorders.
• Analysis of current and developing immunotherapy strategies.
• Discussion of diagnostic limitations and refractory disease variants.

Main Results:

• Shared immunopathogenic pathways identified across different autoimmune neuromuscular disorders.
• Development of targeted therapies including complement inhibition, FcRn antagonism, B-cell depletion, and CAR-T cell therapy.
• Technological advancements are addressing some diagnostic and treatment challenges.

Conclusions:

• Understanding shared mechanisms is crucial for developing effective immunotherapies.
• Targeted strategies show promise but challenges like diagnostic limitations and refractory cases remain.
• Continued research and technological innovation are needed to improve patient outcomes.